Literature DB >> 12939402

Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent on the DF3/MUC1 oncoprotein.

Yongqing Li1, Wei-Hsuan Yu, Jian Ren, Wen Chen, Lei Huang, Surender Kharbanda, Massimo Loda, Donald Kufe.   

Abstract

The DF3/MUC1 transmembrane oncoprotein is aberrantly overexpressed in most human breast carcinomas and interacts with the Wnt effector gamma-catenin. Here, we demonstrate that MUC1 associates constitutively with ErbB2 in human breast cancer cells and that treatment with heregulin/neuregulin-1 (HRG) increases the formation of MUC1-ErbB2 complexes. The importance of the MUC1-ErbB2 interaction is supported by the demonstration that HRG induces binding of MUC1 and gamma-catenin and targeting of the MUC1-gamma-catenin complex to the nucleolus. Significantly, nucleolar localization of gamma-catenin in response to HRG is dependent on MUC1 expression. Moreover, mutation of a RRK motif in the MUC1 cytoplasmic domain abrogates HRG-induced nucleolar localization of MUC1 and gamma-catenin. In concert with these results, we show nucleolar localization of MUC1 and gamma-catenin in human breast carcinomas but not in normal mammary ductal epithelium. These findings demonstrate that MUC1 functions in cross talk between ErbB2 and Wnt pathways by acting as a shuttle for HRG-induced nucleolar targeting of gamma-catenin.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12939402

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  42 in total

Review 1.  Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy.

Authors:  Partha Mukhopadhyay; Subhankar Chakraborty; Moorthy P Ponnusamy; Imayavaramban Lakshmanan; Maneesh Jain; Surinder K Batra
Journal:  Biochim Biophys Acta       Date:  2011-01-26

Review 2.  Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications.

Authors:  Brent N Rexer; Carlos L Arteaga
Journal:  Crit Rev Oncog       Date:  2012

3.  MUC1-C Oncoprotein Interacts Directly with ATM and Promotes the DNA Damage Response to Ionizing Radiation.

Authors:  Lei Huang; Xiaodong Liao; Michael Beckett; Yuan Li; Kum Kum Khanna; Zhugang Wang; Surender Kharbanda; Ralph Weichselbaum; Donald Kufe
Journal:  Genes Cancer       Date:  2010-03

4.  MUC1 oncoprotein functions in activation of fibroblast growth factor receptor signaling.

Authors:  Jian Ren; Deepak Raina; Wen Chen; Guilan Li; Lei Huang; Donald Kufe
Journal:  Mol Cancer Res       Date:  2006-11       Impact factor: 5.852

5.  Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells.

Authors:  Deepak Raina; Rehan Ahmad; Maya Datt Joshi; Li Yin; Zekui Wu; Takeshi Kawano; Baldev Vasir; David Avigan; Surender Kharbanda; Donald Kufe
Journal:  Cancer Res       Date:  2009-06-02       Impact factor: 12.701

Review 6.  Post-translational regulation of signaling mucins.

Authors:  Paul J Cullen
Journal:  Curr Opin Struct Biol       Date:  2011-08-31       Impact factor: 6.809

7.  MUC1-C oncoprotein activates ERK→C/EBPβ signaling and induction of aldehyde dehydrogenase 1A1 in breast cancer cells.

Authors:  Maroof Alam; Rehan Ahmad; Hasan Rajabi; Akriti Kharbanda; Donald Kufe
Journal:  J Biol Chem       Date:  2013-09-16       Impact factor: 5.157

8.  Oncogenic MUC1-C promotes tamoxifen resistance in human breast cancer.

Authors:  Akriti Kharbanda; Hasan Rajabi; Caining Jin; Deepak Raina; Donald Kufe
Journal:  Mol Cancer Res       Date:  2013-03-28       Impact factor: 5.852

9.  MUC1 oncoprotein suppresses activation of the ARF-MDM2-p53 pathway.

Authors:  Deepak Raina; Rehan Ahmad; Dongshu Chen; Shailendra Kumar; Surender Kharbanda; Donald Kufe
Journal:  Cancer Biol Ther       Date:  2008-12-09       Impact factor: 4.742

10.  MUC1 oncoprotein blocks death receptor-mediated apoptosis by inhibiting recruitment of caspase-8.

Authors:  Naoki Agata; Rehan Ahmad; Takeshi Kawano; Deepak Raina; Surender Kharbanda; Donald Kufe
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.